Zai Lab Limited - American Depositary Shares (ZLAB)
31.77
-4.92 (-13.41%)
NASDAQ · Last Trade: Apr 4th, 4:50 PM EDT
A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB).
Via Chartmill · April 3, 2025
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.
Via Talk Markets · March 28, 2025
Via Benzinga · March 28, 2025
Via Benzinga · March 27, 2025

Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering.
Via Benzinga · November 15, 2024

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Via The Motley Fool · February 27, 2025

Via Benzinga · February 18, 2025

Via The Motley Fool · December 5, 2024

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients.
Via Benzinga · December 2, 2024

Via Benzinga · November 15, 2024

The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells.
Via Investor's Business Daily · October 24, 2024

Via Benzinga · October 24, 2024

Via Benzinga · September 25, 2024

Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024.
Via InvestorPlace · July 26, 2024

DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance.
Via InvestorPlace · July 26, 2024

A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock.
Via InvestorPlace · July 26, 2024

Via Benzinga · June 4, 2024

Via Benzinga · June 4, 2024

Via Benzinga · May 9, 2024

Via Benzinga · May 9, 2024